Zou Kelly H, Li Jim Z, Salem Lobna A, Imperato Joseph, Edwards Jon, Ray Amrit
Research, Development and Medical, Upjohn Division, Pfizer Inc, 235 East 42nd Street, MS 235-9-1, New York, NY 10017 USA.
Research, Development and Medical, Upjohn Division, Pfizer Inc, 10777 Science Center Drive, San Diego, CA 92121 USA.
Health Serv Outcomes Res Methodol. 2021;21(1):8-20. doi: 10.1007/s10742-020-00223-7. Epub 2020 Nov 6.
Noncommunicable diseases (NCDs) are the leading causes of mortality and morbidity across the world and factors influencing global poverty and slowing economic development. We summarize how the potential power of real-world data (RWD) and real-world evidence (RWE) can be harnessed to help address the disease burden of NCDs at global, national, regional and local levels. RWE is essential to understand the epidemiology of NCDs, quantify NCD burdens, assist with the early detection of vulnerable populations at high risk of NCDs by identifying the most influential risk factors, and evaluate the effectiveness and cost-benefits of treatments, programs, and public policies for NCDs. To realize the potential power of RWD and RWE, challenges related to data integration, access, interoperability, standardization of analytical methods, quality control, security, privacy protection, and ethical standards for data use must be addressed. Finally, partnerships between academic centers, governments, pharmaceutical companies, and other stakeholders aimed at improving the utilization of RWE can have a substantial beneficial impact in preventing and managing NCDs.
非传染性疾病（NCDs）是全球范围内导致死亡和发病的主要原因，也是影响全球贫困和阻碍经济发展的因素。我们总结了如何利用真实世界数据（RWD）和真实世界证据（RWE）的潜在力量，以帮助在全球、国家、区域和地方层面应对非传染性疾病的疾病负担。真实世界证据对于了解非传染性疾病的流行病学、量化非传染性疾病负担、通过识别最具影响力的风险因素协助早期发现非传染性疾病高风险的脆弱人群，以及评估非传染性疾病治疗、项目和公共政策的有效性和成本效益至关重要。为了实现真实世界数据和真实世界证据的潜在力量，必须解决与数据整合、获取、互操作性、分析方法标准化、质量控制、安全性、隐私保护以及数据使用的道德标准相关的挑战。最后，学术中心、政府、制药公司和其他利益相关者之间旨在提高真实世界证据利用率的伙伴关系，在预防和管理非传染性疾病方面可产生重大有益影响。
